Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | GSR | P00390 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 3/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylacetic Acid SCHEMBL16975021 | 1.00 | AKR1B1 (0.55) | AKR1B1GSRPTGS1ALPIPKM | |
| Lysine SCHEMBL28231846 | 0.95 | GSR (0.62) | AKR1B1GSRPTGS1ALPIPKM | |
| Lysine SCHEMBL28268261 | 0.94 | GSR (0.61) | AKR1B1GSRPTGS1ALPIPKM | |
| Felbinac SCHEMBL29711520 | 0.87 | ABCC4 (0.58) | AKR1B1GSRPTGS1MMP2POLB | |
| Felbinac SCHEMBL1231150 | 0.87 | ABCC4 (0.58) | AKR1B1GSRPTGS1MMP2POLB | |
| Dl-Phenylalanine SCHEMBL4361765 | 0.85 | SLC7A5 (0.73) | GSRPTGS1ALPIPKMXIAP | |
| Phenylalanine SCHEMBL1537318 | 0.85 | SLC7A5 (0.73) | GSRPTGS1ALPIPKMXIAP | |
| Phenylacetic Acid SCHEMBL7798556 | 0.85 | PTGS1 (0.46) | AKR1B1GSRPTGS1ALPIPKM | |
| Phenaceturic Acid SCHEMBL17164600 | 0.84 | MMP2 (0.47) | GSRPTGS1ALPIPKMXIAP | |
| Phenaceturic Acid SCHEMBL17164601 | 0.84 | MMP2 (0.47) | GSRPTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731232-A1 | POROUS CARBON PARTICLES FOR USE IN THERAPY | UCL Business Ltd (GB) | 2026-04-29 | — | — | EP | claimed |
| EP-3716933-B1 | WHITENING COMPOSITIONS AND METHODS FOR INCREASING STABILITY OF THE SAME | COLGATE PALMOLIVE CO (US) | 2026-01-07 | — | — | EP | claimed |
| US-12516015-B2 | L-ornithine phenyl acetate and methods of making thereof | AMALIVE LIMITED (GB) | 2026-01-06 | — | — | US | claimed |
| US-12396675-B2 | Methods of assessing hepatic encephalopathy | AMALIVE LIMITED (GB) | 2025-08-26 | — | — | US | claimed |
| US-20250170157-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | LEXICON PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | claimed |
| EP-4200350-B1 | POLYOL FORMULATIONS AND A METHOD FOR THE PREPARATION OF PUR/PIR FOAMS BASED ON THESE POLYOL FORMULATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2025-05-21 | — | — | EP | claimed |
| WO-2025101731-A1 | SGLT1 INHIBITORS FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | LEXICON PHARMACEUTICALS, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| WO-2024261472-A1 | POROUS CARBON PARTICLES FOR USE IN THERAPY | YAQRIT LIMITED (GB) | 2024-12-26 | — | — | WO | claimed |
| WO-2024261477-A1 | COMBINATION OF TLR4 ANTAGONIST, ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE | YAQRIT LIMITED (GB) | 2024-12-26 | — | — | WO | claimed |
| WO-2024256516-A1 | USE OF POLYALKYLENE GLYCOLS AS ANTIFREEZE AGENTS IN AN AQUEOUS LUBRICANT COMPOSITION | TOTALENERGIES ONETECH (FR) | 2024-12-19 | — | — | WO | claimed |
| WO-2017053613-A1 | TREATMENT AND PREVENTION OF NEURONAL CELL LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE | OCERA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | claimed |
| US-20170056416-A1 | STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | UMECRINE COGNITION AB (SE) | 2017-03-02 | — | — | US | claimed |
| WO-2017031131-A1 | TREATMENT AND PREVENTION OF MUSCLE LOSS USING L-ORNITHINE IN COMBINATION WITH AT LEAST ONE OF PHENYLACETATE AND PHENYLBUTYRATE | OCERA THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | WO | claimed |
| EP-3099306-A1 | STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | Umecrine Cognition AB (SE) | 2016-12-07 | — | — | EP | claimed |
| US-20160339040-A1 | STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | UMECRINE COGNITION AB (SE) | 2016-11-24 | — | — | US | claimed |
| US-20160338982-A1 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE | OCERA THERAPEUTICS LLC | 2016-11-24 | — | — | US | claimed |
| WO-2016172112-A1 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE | OCERA THERAPEUTICS, INC. (US) | 2016-10-27 | — | — | WO | claimed |
| WO-2016085887-A1 | TREATMENT OF DISEASES ASSOCIATED WITH HEPATIC STELLATE CELL ACTIVATION USING AMMONIA-LOWERING THERAPIES | UCL BUSINESS PLC (GB) | 2016-06-02 | — | — | WO | claimed |
| WO-2015114308-A1 | STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | UMECRINE COGNITION AB (SE) | 2015-08-06 | — | — | WO | claimed |
| CN-102421432-A | L-ornithine phenylacetate and preparation method thereof | OCERA THERAPEUTICS INC | 2012-04-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056416-A1 | STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | CYP11B2, CYP11B1, HSD17B2 | AKR1B1 89/4885GSR 507/4885PTGS1 75/4885 |
| US-20160338982-A1 | FORMULATIONS OF L-ORNITHINE PHENYLACETATE | OAT, OTC, ODC1 | AKR1B1 199/4885GSR 1899/4885PTGS1 1718/4885 |
| US-20160339040-A1 | STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY | CYP11B2, CYP11B1, HSD17B2 | AKR1B1 89/4885GSR 507/4885PTGS1 75/4885 |
| US-20250170157-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATIC ENCEPHALOPATHY | OAT, GYS2, OTC | AKR1B1 758/4885GSR 175/4885PTGS1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.